Stockreport

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]

Aura Biosciences, Inc.  (AURA) 
PDF Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across Non-ocular So [Read more]